PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

PD-1/PD-L1 Related Products (291)
Antibodies (8)

By Effects:	Ligands (3) Inhibitors (233) Agonist (1) Degraders (3) Antagonists (5) Activators (5) Modulators (4) Inducers (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-162644

Antitumor agent-170	Inhibitor
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC₅₀ of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a K_i of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics.

HY-P99679

Izuralimab	Inhibitor
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.

HY-161518

PD-1/PD-L1-IN-44	Inhibitor
PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits PD-1/PD-L1 proteins (IC₅₀=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8⁺ cell infiltration.

HY-167840

IMMH-010 maleate	Inhibitor
IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.

HY-P99723

Manelimab
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1).

HY-172396

PD-L1/VISTA-IN-2	Inhibitor
PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC₅₀ of 1.4 μM for PD-L1 and a K_D of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects.

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	Inhibitor
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279.

HY-156085

LP23	Inhibitor
LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC₅₀: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg).

HY-P990824

Anti-Mouse PD-1 Antibody (J43)	Inhibitor
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to PD-1. The recommend isotype control of Anti-Mouse PD-1 Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-156149

CYP51/PD-L1-IN-1	Inhibitor
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC₅₀: 0.884 μM) and PD-L1 (IC₅₀: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.

HY-162357

PD-L1-IN-5	Inhibitor
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo.

HY-155115

LSD1-IN-27	Inhibitor	98.88%
LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer.

HY-159892

PD-1/PD-L1-IN-54	Inhibitor
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1.

HY-144746

PD-1/PD-L1-IN-26	Inhibitor
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases.

HY-157811

PD-1/PD-L1-IN-40	Inhibitor
PD-1/PD-L1-IN-40 (Compound EP16) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer.

HY-168530

PDL1 degrader-1	Degrader
PDL1 degrader-1 (compound PMT-O9-1A) is a potent PD-L1 degrader. PDL1 degrader-1 decreases the protein expression of PD-L1. PDL1 degrader-1 shows cytotoxicity. PDL1 degrader-1 shows anticancer activity.

HY-P10838

PL120131	Inhibitor
PL120131 is a PD-1/PD-L1 inhibitory peptide that can interfere with the interaction of PD-1/PD-L1 by binding to PD-1. PL120131 is capable of inhibiting the PD-1-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs).

HY-169434

LTB	Inhibitor
LTB is a prodrug formed by coupling glycolysis inhibitor (Lonidamine (HY-B0486)) with PD1/PDL1 blocker (BMS-1 (HY-19991)) by thioketal linkage. LTB can further encapsulate photosensitizer chlorine e6 (Ce6) (HY-13594) to construct a co-delivery photodynamic nanoplatform (LTB-6 NPs) by self-assembly.

HY-144443

PD-1/PD-L1-IN-16	Inhibitor
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of PD-1/PD-L1 with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch.

HY-173070

TLR7 agonist 29	Activator
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC.

Name
Email *

	Sorry, but the email address you supplied was invalid.

PD-1/PD-L1

PD-1/PD-L1

PD-1/PD-L1 Related Products (291)

Antibodies (8)

PD-1/PD-L1 Related Products (291):